^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
Oncomine™ BCR IGH-SR Assay

Type:
Laboratory Developed Test
Related tests:
Evidence

News

1year
Innovations in Critical Care Education: Lessons from Kenya (ATS 2023)
There is no abstract associated with this presentation.
Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
Oncomine™ BCR IGH-SR Assay
1year
TISSUE B-CELL RECEPTOR REPERTOIRE AS BIOMARKER OF COMPLETE PATHOLOGICAL RESPONSE IN NSCLC PATIENTS TREATED WITH NEOADJUVANT CHEMOIMMUNOTHERAPY (NADIM TRIALS) (ELCC 2023)
In post-treatment samples (n = 40), no differences were observed in any clonal/lineage derived metrics between CPR (n = 22) and non-CPR tumors (n = 18). Conclusions Our results support the association between an uneven and less diverse distribution of B cell clones and lineages proportions at diagnosis with complete pathological response after neoadjuvant CI.
Clinical • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
Oncomine™ BCR IGH-SR Assay
over2years
Fully Automated Workflows Quantify and Report Key T-Cell and B-Cell Receptor Biomarkers Relevant to Immuno-Oncology and Heme-Oncology Research (ASH 2021)
(2021) Early changes in the circulating T cells are associated with clinical outcomes after PD‑L1 blockade by durvalumab in advanced NSCLC patients...Journal of Immunotherapy and Precision Oncology. 2 (4): 137–143.
PD(L)-1 Biomarker • IO biomarker
|
TRB (T Cell Receptor Beta Locus)
|
Oncomine™ BCR IGH-SR Assay • Oncomine™ TCR Beta-SR Assay
|
Imfinzi (durvalumab)
over2years
[VIRTUAL] SAKK 16/14 - T - Cell Receptor Repertoire Metrics Predict Response to Neoadjuvant Durvalumab in Patients With Stage IIIA(N2) NSCLC (IASLC-WCLC 2021)
"Here, we performed TCR sequencing in patients from the phase 2 trial SAKK 16/14 undergoing neoadjuvant chemotherapy with three cycles of cisplatin/docetaxel followed by treatment with the PD-L1 antibody durvalumab. In contrast, TMB was not associated with EFS, MPR or nodal clearance (p=0.91, p=0.47, p=0.52). Conclusion Our results show that TCR repertoire measured in peripheral blood samples and tumor tissue may provide a useful tool for predicting risk of recurrence after neoadjuvant sequential chemo-immunotherapy with durvalumab in patients with resectable stage IIIA(N2) NSCLC."
Clinical
|
TMB (Tumor Mutational Burden)
|
FoundationOne® CDx • Oncomine™ BCR IGH-LR Assay • Oncomine™ BCR IGH-SR Assay • Oncomine™ Comprehensive Assay Plus
|
cisplatin • Imfinzi (durvalumab) • docetaxel